aff
Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results2015· article· en· Journal for ImmunoTherapy of Cancer· Medicine
214
citations